Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer

Journal of Clinical Oncology

Volumn 27, Issue 2, 2009, Pages 186-192

  Salama, Paul ^a   Phillips, Michael ^a   Grieu, Fabienne ^a   Morris, Melinda ^a   Zeps, Nik ^a   Joseph, David ^a   Platell, Cameron ^a   Iacopetta, Barry ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD45RO ANTIGEN; CD8 ANTIGEN; TRANSCRIPTION FACTOR FOXP3; CD45 ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN;

ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL DENSITY; COLORECTAL CANCER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; TISSUE MICROARRAY; BIOSYNTHESIS; COLORECTAL TUMOR; IMMUNOLOGY; MULTIVARIATE ANALYSIS; PATHOLOGY; TUMOR ASSOCIATED LEUKOCYTE;

ANTIGENS, CD45; CD8-POSITIVE T-LYMPHOCYTES; COLORECTAL NEOPLASMS; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES, TUMOR-INFILTRATING; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; T-LYMPHOCYTES, REGULATORY;

EID: 58249089749     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.7229     Document Type: Article

References (40)

1. House AK, Watt AG: Survival and the immune response in patients with carcinoma of the colorectum. Gut 20:868-874, 1979
2. Svennevig JL, Lunde OC, Holter J, et al: Lymphoid infiltration and prognosis in colorectal carcinoma. Br J Cancer 49:375-377, 1984
3. Jass JR: Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol 39:585-589, 1986
4. Halvorsen TB, Seim E: Association between invasiveness, inflammatory reaction, desmoplasia and survival in colorectal cancer. J Clin Pathol 42:162-166, 1989
5. Murphy J, O'Sullivan GC, Lee G, et al: The inflammatory response within Dukes' B colorectal cancers: Implications for progression of micrometastases and patient survival. Am J Gastroenterol 95:3607-3614, 2000
6. Ohtani H: Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun 7:4, 2007
7. Naito Y, Saito K, Shiiba K, et al: CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58:3491-3494, 1998
8. Nagtegaal ID, Marijnen CA, Kranenbarg EK, et al: Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect-a histopathological and immunohistochemical study. BMC Cancer 1:7, 2001
9. Menon AG, Janssen-van Rhijn CM, Morreau H, et al: Immune system and prognosis in colorectal cancer: A detailed immunohistochemical analysis. Lab Invest 84:493-501, 2004
10. Prall F, Dührkop T, Weirich V, et al: Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol 35:808-816, 2004
11. Chiba T, Ohtani H, Mizoi T, et al: Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: Possible association with suppression of micrometastasis. Br J Cancer 91:1711-1717, 2004
12. Pagès F, Berger A, Camus M, et al: Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353:2654-2666, 2005
13. Koch M, Beckhove P, Op den Winkel J, et al: Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ. Ann Surg 244:986-992, 2006
14. Galon J, Costes A, Sanchez-Cabo F, et al: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960-1964, 2006
15. Oberg A, Samii S, Stenling R, et al: Different occurrence of CD8+, CD45R0+, and CD68+ immune cells in regional lymph node metastases from colorectal cancer as potential prognostic predictors. Int J Colorectal Dis 17:25-29, 2002
16. Curiel TJ: Tregs and rethinking cancer immunotherapy. J Clin Invest 117:1167-1174, 2007
17. Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295-307, 2006
18. Needham DJ, Lee JX, Beilharz MW: Intratumoural regulatory T cells: A potential new target in cancer immunotherapy. Biochem Biophys Res Commun 343:684-691, 2006
19. Clarke SL, Betts GJ, Plant A, et al: CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS ONE 1:e129, 2006
20. Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4:330-336, 2003
21. Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057-1061, 2003
22. Curiel TJ, Coukos G, Zou L, et al: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942-949, 2004
23. Sato E, Olson SH, Ahn J, et al: Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 102:18538-18543, 2005
24. Hiraoka N, Onozato K, Kosuge T, et al: Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 12:5423-5434, 2006
25. Kobayashi N, Hiraoka N, Yamagami W, et al: FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 13:902-911, 2007
26. Gao Q, Qiu SJ, Fan J, et al: Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25:2586-2593, 2007
27. Loddenkemper C, Schernus M, Noutsias M, et al: In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer. J Transl Med 4:52, 2006
28. Ling KL, Pratap SE, Bates GJ, et al: Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun 7:7, 2007
29. Chai SM, Zeps N, Shearwood AM, et al: Screening for defective DNA mismatch repair in stage II and III colorectal cancer patients. Clin Gastroenterol Hepatol 2:1017-1025, 2004
30. Harrell FE Jr, Lee KL, Mark DB: Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361-387, 1996
31. Miracco C, Mourmouras V, Biagioli M, et al: Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma. Oncol Rep 18:1115-1122, 2007
32. Bates GJ, Fox SB, Han C, et al: Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24:5373-5380, 2006
33. Quirke P, Morris E: Reporting colorectal cancer. Histopathology 50:103-112, 2007
34. Morris M, Platell C, de Boer B, et al: Population-based study of prognostic factors in stage II colonic cancer. Br J Surg 93:866-871, 2006
35. Stewart CJ, Morris M, de Boer B, et al: Identification of serosal invasion and extramural venous invasion on review of Dukes' stage B colonic carcinomas and correlation with survival. Histopathology 51:372-378, 2007
36. Alvaro T, Lejeune M, Salvadó MT, et al: Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 24:5350-5357, 2006
37. Roncarolo MG, Gregori S: Is FOXP3 a bona fide marker for human regulatory T cells? Eur J Immunol 38:925-927, 2008
38. Roncador G, Brown PJ, Maestre L, et al: Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol 35:1681-1691, 2005
39. Walker MR, Carson BD, Nepom GT, et al: De novo generation of antigen-specific CD4+CD25+ regulatory T cells from human CD4+CD25- cells. Proc Natl Acad Sci U S A 102:4103-4108, 2005
40. Wang J, Ioan-Facsinay A, van der Voort E, et al: Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 37:129-138, 2007